Mizuho Said Adaptimmune Therapeutics plc (ADAP) ASCO Data 'Incrementally Supportive'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. ANT
4. META
5. FICO
6. LLY
7. TSLA
8. MSFT
9. SPCX
10. AZN

Go back to Mizuho Said Adaptimmune Therapeutics plc (ADAP) ASCO Data 'Incrementally Supportive'

SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers – Late Stage Development Initiated in EGJ Cancer

May 29, 2020 7:30 AM EDT

- New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy -

- Durability and efficacy data presented at ASCO support potential for SPEARHEAD-1 as a registrational trial for sarcoma - commercial launch planned in the US in 2022 -

- Phase 2 trial combining ADP-A2M4 with pembrolizumab in head and neck cancer (SPEARHEAD-2) will be the first time a SPEAR T-cell therapy is used in sequence with first line systemic therapy -

-... More